news and events

Quick Link

Funded by the European Union. Views and opinions expressed are however those of the author(s) only
and do not necessarily reflect those of the European Union or HADEA. Neither
the European Union nor the granting authority can be held responsible for them.

CANCERNA Partners held a face-to-face meeting on September 5-6, 2022 meeting in Jerusalem

Breakthrough RNA-Based Anti-Cancer Immunotherapy Treatments Being Developed by Global Consortium led by the Hadassah Cancer Research Institute

HADASSAH AND DRUG GIANT MERCK LAUNCH MRNA INITIATIVE TO FIGHT CANCER

Immunyx Pharma Part of Global Consortium CanceRNA Developing RNA-based Cancer Vaccine

NMD inhibition by 5-azacytidine augments presentation of immunogenic frameshift-derived neoepitopes

Quick Link

Contact Info